WAVE Life Sciences Ltd. (NASDAQ:WVE) Director Masaharu Tanaka sold 20,747 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $24.21, for a total value of $502,284.87. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of WAVE Life Sciences Ltd. (NASDAQ WVE) opened at 24.15 on Wednesday. The company has a 50-day moving average price of $20.60 and a 200-day moving average price of $21.56. WAVE Life Sciences Ltd. has a 52 week low of $15.15 and a 52 week high of $40.15. The stock’s market cap is $670.40 million.

WAVE Life Sciences (NASDAQ:WVE) last released its earnings results on Wednesday, August 9th. The company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by ($0.14). The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.73 million. WAVE Life Sciences had a negative net margin of 3,375.12% and a negative return on equity of 55.19%. Equities analysts anticipate that WAVE Life Sciences Ltd. will post ($3.71) EPS for the current year.

TRADEMARK VIOLATION WARNING: “WAVE Life Sciences Ltd. (WVE) Director Masaharu Tanaka Sells 20,747 Shares of Stock” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/20/wave-life-sciences-ltd-wve-director-masaharu-tanaka-sells-20747-shares-of-stock.html.

Institutional investors and hedge funds have recently bought and sold shares of the stock. American International Group Inc. boosted its holdings in WAVE Life Sciences by 7.1% during the 1st quarter. American International Group Inc. now owns 4,554 shares of the company’s stock valued at $125,000 after acquiring an additional 302 shares during the period. Nationwide Fund Advisors boosted its holdings in WAVE Life Sciences by 58.1% during the 2nd quarter. Nationwide Fund Advisors now owns 6,720 shares of the company’s stock valued at $125,000 after acquiring an additional 2,470 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in WAVE Life Sciences by 71.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,422 shares of the company’s stock valued at $175,000 after acquiring an additional 3,912 shares during the period. Strs Ohio boosted its holdings in WAVE Life Sciences by 6.3% during the 2nd quarter. Strs Ohio now owns 11,900 shares of the company’s stock valued at $221,000 after acquiring an additional 700 shares during the period. Finally, Rhumbline Advisers boosted its holdings in WAVE Life Sciences by 62.3% during the 2nd quarter. Rhumbline Advisers now owns 12,502 shares of the company’s stock valued at $233,000 after acquiring an additional 4,800 shares during the period. Institutional investors own 69.58% of the company’s stock.

WVE has been the subject of a number of analyst reports. Mizuho set a $34.00 price objective on WAVE Life Sciences and gave the company a “buy” rating in a research note on Friday, August 18th. JMP Securities reissued an “outperform” rating and set a $40.00 price objective on shares of WAVE Life Sciences in a research note on Friday, June 9th. BidaskClub raised WAVE Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. ValuEngine lowered WAVE Life Sciences from a “hold” rating to a “sell” rating in a research note on Friday, June 16th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $40.00 price objective (down previously from $42.00) on shares of WAVE Life Sciences in a research note on Thursday, August 10th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. WAVE Life Sciences currently has a consensus rating of “Hold” and an average price target of $40.00.

About WAVE Life Sciences

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Receive News & Stock Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related stocks with our FREE daily email newsletter.